The COVID19 vaccine and market implications

The COVID-19 vaccine and market implications

It has been over a year since the first cases of COVID-19 were diagnosed in Wuhan, China. As a result of the virus, we have seen an unfathomable global shutdown in Q2, followed by a record-setting return to growth in Q3 as the summer months arrived. Q4 resulted in second and third waves. In November, results of Phase 3 vaccine studies began to trickle in and by the end of the year, frontline workers and those most in need were already receiving the first doses.

US Annualised GDP Growth Rate:

Source: Trading Economics, BLS

The first few months of 2021 will likely continue in the same manner as 2020 ended:

  • threats of global lockdowns and restrictions as the virus lingers
  • depressed economic data, primarily in services
  • additional fiscal and monetary support from governments and central banks around the world

As we move into Q2 and the vaccines become more widely available, things should begin to return to the “old normal.” However, although a return to the “old normal” may be better for daily life, it may not be so great for the markets. As we move through 2021, below are some markets to watch as the vaccine is dispersed:

Economic Data outlook

As we progress through the year, employment should pick up and initial claims should decrease. As people return to work after being cooped up for the better part of a year, PMIs should continue to recover, especially in the services industries. Industries such as food services, cruise lines, airlines, and hospitality could outperform. The “stay at home” industries, such as technology (which includes FAANG stocks) may underperform. GDP should continue to rise – however, the growth rate may begin to level off towards the end of the year. Housing should stay strong on the back of a demographic tailwind and millennials seeking to “beat the rush” in anticipation of higher interest rates. (For insight on Joe Biden's policy implications, click here)

The Covid 19 impact on the US Dollar

With a vaccine on the way and more people returning to work, there will be less need for fiscal and monetary stimulus; however many central banks have indicated that they will keep monetary policy accommodative through 2021. The US Dollar could remain under pressure through the first half of the year but may rebound heading into Q3 and Q4 as the FOMC may hint at raising interest rates if inflation picks up heading into in 2022.

To put it simply, better economic data equals less stimulus. Less stimulus means less US Dollars in the system. Less US Dollars (plus higher demand for products and services) equals higher price.

On a monthly timeframe, the DXY has broken below the upward sloping trendline from September 2011. If that level breaks, watch for the 50% retracement level from the February 2008 lows to the January 2017 highs as the next support level, near 87.10.  Below there was the 50% retracement level near 87.26 and the horizontal support near 84.60.

Source: Tradingview, GAIN Capital

Coronavirus vaccine effect on global stocks

The Dow Jones Industrial Average traded above 30,000 for the first time ever in November.  The S&P 500 and NASDAQ are near all-time highs.  As the vaccine is introduced to the world population and lockdowns are lifted, we should see a rotation out of “stay at home” stocks and a return to value stocks. Keep in mind however that as the Federal Reserve and other central banks begin to worry less about stimulus and more about inflation in Q3 or Q4, stocks might not be as excited and may begin to turn lower.  In the Dow, 32,700 is the 127.2% Fibonacci extension from the highs during the week of February 10th to the lows the week of March 23rd:

Source: Tradingview, GAIN Capital

2-year yields forecast

With the introduction of a vaccine to the general public in the first half of the year, 2-year yields should remain between 0%-0.25%. If the word “inflation” enters the FOMC’s vocabulary during this year, rates should turn higher, which may be dramatic as the market tries to price in inflation expectations.

Source: Tradingview, GAIN Capital

Covid 19 vaccine to boost crude oil

As more and more people around the world receive the vaccine, demand for manufacturing will increase. Travel will begin to return to normal and airlines and cruise ships will return to normal operations. The increase in demand could serve as a tailwind for the price for oil. Watch for WTI to continue to move higher as a vaccine is rolled out, possibly testing the January 2020 highs of $65.66.

Source: Tradingview, GAIN Capital

As pharmaceutical companies release more and more of the COVID-19 vaccine, economies should begin to recover, and life will revert to the “old normal”. However, that doesn’t necessarily mean it will be good for the markets as central banks may begin using the words “inflation” and “less stimulus”.

For insight into how tech stocks could perform in 2021, click here.



This report is intended for general circulation only. It should not be construed as a recommendation, or an offer (or solicitation of an offer) to buy or sell any financial products. The information provided does not take into account your specific investment objectives, financial situation or particular needs. Before you act on any recommendation that may be contained in this report, independent advice ought to be sought from a financial adviser regarding the suitability of the investment product, taking into account your specific investment objectives, financial situation or particular needs.

StoneX Financial Pte. Ltd., may distribute reports produced by its respective foreign entities or affiliates within the StoneX group of companies or third parties pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed to a person in Singapore who is not an accredited investor, expert investor or an institutional investor (as defined in the Securities Futures Act), StoneX Financial Pte. Ltd. accepts legal responsibility to such persons for the contents of the report only to the extent required by law. Singapore recipients should contact StoneX Financial Pte. Ltd. at 6826 9988 for matters arising from, or in connection with the report.

In the case of all other recipients of this report, to the extent permitted by applicable laws and regulations neither StoneX Financial Pte. Ltd. nor its associated companies will be responsible or liable for any loss or damage incurred arising out of, or in connection with, any use of the information contained in this report and all such liability is hereby expressly disclaimed. No representation or warranty is made, express or implied, that the content of this report is complete or accurate.

StoneX Financial Pte. Ltd. is not under any obligation to update this report.

Trading CFDs and FX on margin carries a high level of risk that may not be suitable for some investors. Consider your investment objectives, level of experience, financial resources, risk appetite and other relevant circumstances carefully. The possibility exists that you could lose some or all of your investments, including your initial deposits. If in doubt, please seek independent expert advice. Visit www.cityindex.com/en-sg/terms-and-policies for the complete Risk Disclosure Statement.

ALL TRADING INVOLVES RISKS. LOSSES CAN EXCEED DEPOSITS.

City Index is a trading name of StoneX Financial Pte. Ltd. (“SFP”) for the offering of dealing services in Contracts for Differences (“CFD”). SFP holds a Capital Markets Services Licence issued by the Monetary Authority of Singapore for Dealing in Exchange-Traded Derivatives Contracts, Over-the-Counter Derivatives Contracts, and Spot Foreign Exchange Contracts for the Purposes of Leveraged Foreign Exchange Trading. SFP is also both Derivatives Trading and Clearing member of the Singapore Exchange (“SGX”). SFP is a wholly-owned subsidiary of StoneX Group Inc.

The information provided herein is intended for general circulation. It does not take into account the specific investment objectives, financial situation or particular needs of any particular person. You should take into account your specific investment objectives, financial situation or particular needs before making a commitment to invest, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit. No representation or warranty is given as to the accuracy or completeness of this information. Consequently, any person acting on it does so entirely at their own risk.

The information does not represent an offer of, or solicitation for, a transaction in any investment product. Any views and opinions expressed may be changed without an update. To understand the risks and costs involved, please visit the section captioned “Important Information” and the “Risk Disclosure Statement”.

The information herein is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.

StoneX Financial Pte. Ltd. 1 Raffles Place, #18-61, One Raffles Place Tower 2, Singapore 048616. Tel: 6309 1000. Co. Reg. No.: 201130598R.

This advertisement has not been reviewed by the Monetary Authority of Singapore.

© City Index 2024